S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
NASDAQ:OABI

OmniAb (OABI) Stock Price, News & Analysis

$6.17
+0.05 (+0.82%)
(As of 12/29/2023 ET)
Today's Range
$6.05
$6.20
50-Day Range
$4.23
$6.17
52-Week Range
$3.07
$6.20
Volume
1.01 million shs
Average Volume
681,110 shs
Market Capitalization
$717.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.17

OmniAb MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.6% Upside
$9.17 Price Target
Short Interest
Bearish
5.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$405,650 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

563rd out of 950 stocks

Biotechnology Industry

9th out of 24 stocks


OABI stock logo

About OmniAb Stock (NASDAQ:OABI)

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OABI Stock Price History

OABI Stock News Headlines

OmniAb (NASDAQ:OABI) Reaches New 1-Year High at $5.98
President of OmniAb Matthew Foehr Buys 8.2% More Shares
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
OmniAb files for $300M mixed shelf
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
Matthew Foehr Bought 4.1% More Shares In OmniAb
OmniAb Appoints Steve Love to its Board of Directors
OmniAb: Hold For Growth
OABIW OmniAb, Inc. WT EXP 110127
OmniAb President Acquires 2.0% More Stock
See More Headlines
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OABI
Fax
N/A
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.17
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+48.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-22,330,000.00
Pretax Margin
-53.64%

Debt

Sales & Book Value

Annual Sales
$59.08 million
Book Value
$2.96 per share

Miscellaneous

Free Float
108,101,000
Market Cap
$717.20 million
Optionable
Not Optionable
Beta
-0.40
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Matthew W. Foehr (Age 50)
    President, CEO & Director
    Comp: $967.72k
  • Mr. Kurt A. Gustafson (Age 55)
    Executive VP of Finance & CFO
    Comp: $558.48k
  • Mr. Charles S. Berkman J.D. (Age 54)
    Chief Legal Officer & Secretary
    Comp: $734.33k
  • Ms. Cia McCaffrey
    Vice President of People & Talent
  • Dr. Bill Harriman Ph.D.
    Senior Vice President of Antibody Discovery
  • Ms. Marie-Cecile van de Lavoir D.V.M.
    Ph.D., Senior Vice President of Technical Operations & Genetics
  • Dr. Christel Iffland Ph.D.
    Senior Vice President of Antibody Technologies
  • Dr. Douglas S. Krafte Ph.D. (Age 65)
    Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
  • Ms. Donna Ventura CPA
    Senior Vice President of Corporate Controller














OABI Stock Analysis - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OABI shares.
View OABI analyst ratings
or view top-rated stocks.

What is OmniAb's stock price target for 2024?

6 analysts have issued 12 month price objectives for OmniAb's stock. Their OABI share price targets range from $6.00 to $11.00. On average, they predict the company's stock price to reach $9.17 in the next year. This suggests a possible upside of 48.6% from the stock's current price.
View analysts price targets for OABI
or view top-rated stocks among Wall Street analysts.

How have OABI shares performed in 2023?

OmniAb's stock was trading at $3.60 on January 1st, 2023. Since then, OABI stock has increased by 71.4% and is now trading at $6.17.
View the best growth stocks for 2023 here
.

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our OABI earnings forecast
.

How were OmniAb's earnings last quarter?

OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The company had revenue of $5.48 million for the quarter, compared to analysts' expectations of $11.37 million. OmniAb had a negative trailing twelve-month return on equity of 8.88% and a negative net margin of 45.99%.

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OABI) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -